These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 25552385)

  • 21. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
    Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aromatase inhibitors and their antitumor effects in model systems.
    Brodie A; Lu Q; Liu Y; Long B
    Endocr Relat Cancer; 1999 Jun; 6(2):205-10. PubMed ID: 10731110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
    Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R
    J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
    Thrane S; Pedersen AM; Thomsen MB; Kirkegaard T; Rasmussen BB; Duun-Henriksen AK; Lænkholm AV; Bak M; Lykkesfeldt AE; Yde CW
    Oncogene; 2015 Aug; 34(32):4199-210. PubMed ID: 25362855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer.
    Leclercq G; Devleeschouwer N; Heuson JC
    J Steroid Biochem; 1983 Jul; 19(1A):75-85. PubMed ID: 6887875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
    Goto W; Kashiwagi S; Asano Y; Takada K; Morisaki T; Takahashi K; Fujita H; Shibutani M; Amano R; Takashima T; Tomita S; Hirakawa K; Ohira M
    BMC Cancer; 2020 Dec; 20(1):1215. PubMed ID: 33302911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor.
    Zajchowski DA; Sager R; Webster L
    Cancer Res; 1993 Oct; 53(20):5004-11. PubMed ID: 8402691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
    McClements L; Annett S; Yakkundi A; O'Rourke M; Valentine A; Moustafa N; Alqudah A; Simões BM; Furlong F; Short A; McIntosh SA; McCarthy HO; Clarke RB; Robson T
    BMC Cancer; 2019 Apr; 19(1):351. PubMed ID: 30975104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
    Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
    Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells.
    Watts CK; Sweeney KJ; Warlters A; Musgrove EA; Sutherland RL
    Breast Cancer Res Treat; 1994; 31(1):95-105. PubMed ID: 7981461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells.
    Deng H; Yin L; Zhang XT; Liu LJ; Wang ML; Wang ZY
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():417-26. PubMed ID: 25158023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
    Wang B; Li D; Rodriguez-Juarez R; Farfus A; Storozynsky Q; Malach M; Carpenter E; Filkowski J; Lykkesfeldt AE; Kovalchuk O
    BMC Cancer; 2018 Aug; 18(1):817. PubMed ID: 30103729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer.
    Smith JW; Vukelja S; Hoffman AD; Jones VE; McIntyre K; Berrak E; Song JX; O'Shaughnessy J
    Clin Breast Cancer; 2016 Feb; 16(1):31-7. PubMed ID: 26433876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models.
    Niwa Y; Asano M; Nakagawa T; France D; Semba T; Funahashi Y
    Anticancer Res; 2020 Dec; 40(12):6699-6712. PubMed ID: 33288563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor activity of a novel antiestrogen (Analog II) on human breast cancer cells.
    Jain PT; Rajah TT; Pento JT
    Anticancer Drugs; 1997 Nov; 8(10):964-73. PubMed ID: 9436640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens.
    Wilcken NR; Prall OW; Musgrove EA; Sutherland RL
    Clin Cancer Res; 1997 Jun; 3(6):849-54. PubMed ID: 9815758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
    Jansen GH; Franke HR; Wolbers F; Brinkhuis M; Vermes I
    Climacteric; 2008 Aug; 11(4):315-21. PubMed ID: 18645697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eribulin mesylate.
    Jain S; Vahdat LT
    Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Downregulation of retinoblastoma protein is involved in the enhanced cytotoxicity of 4-hydroxytamoxifen plus mifepristone combination therapy versus antiestrogen monotherapy of human breast cancer.
    Schoenlein PV; Hou M; Samaddar JS; Gaddy VT; Thangaraju M; Lewis J; Johnson M; Ganapathy V; Kallab A; Barrett JT
    Int J Oncol; 2007 Sep; 31(3):643-55. PubMed ID: 17671693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer.
    Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T
    J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.